Drug intelligence / Profile preview

ORYN1002

Development stage: Preclinical
Lead developer: Oryn Therapeutics
Modality: Peptides
Administration: Subcutaneous

Overview

ORYN1002 is a next-generation macrocyclic peptide therapeutic candidate developed by Oryn Therapeutics for the treatment of inflammatory and autoimmune diseases. Built on the company's proprietary Orynotide platform, ORYN1002 is designed to modulate allosteric control points on proteins that regulate inflammatory and tissue-remodeling pathways. The molecule is optimized for once-weekly subcutaneous administration, incorporating pharmacological learnings from the company's earlier program, ORTD-1. It is currently in the IND-enabling stage of development.

Beyond the preview

Go deeper on ORYN1002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ORYN1002.

Explore the full profile